328 related articles for article (PubMed ID: 34440231)
1. How Are Adenosine and Adenosine A
Mori A; Cross B; Uchida S; Kerrick Walker J; Ristuccia R
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440231
[TBL] [Abstract][Full Text] [Related]
2. Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors.
Sebastião AM; Rei N; Ribeiro JA
Front Pharmacol; 2018; 9():267. PubMed ID: 29713276
[TBL] [Abstract][Full Text] [Related]
3. Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis.
Ng SK; Higashimori H; Tolman M; Yang Y
Exp Neurol; 2015 May; 267():115-22. PubMed ID: 25779930
[TBL] [Abstract][Full Text] [Related]
4. A2A adenosine receptors are up-regulated in lymphocytes from amyotrophic lateral sclerosis patients.
Vincenzi F; Corciulo C; Targa M; Casetta I; Gentile M; Granieri E; Borea PA; Popoli P; Varani K
Amyotroph Lateral Scler Frontotemporal Degener; 2013 Sep; 14(5-6):406-13. PubMed ID: 23679925
[TBL] [Abstract][Full Text] [Related]
5. Presymptomatic and symptomatic ALS SOD1(G93A) mice differ in adenosine A1 and A2A receptor-mediated tonic modulation of neuromuscular transmission.
Nascimento F; Sebastião AM; Ribeiro JA
Purinergic Signal; 2015 Dec; 11(4):471-80. PubMed ID: 26335190
[TBL] [Abstract][Full Text] [Related]
6. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
Cervetto C; Frattaroli D; Maura G; Marcoli M
Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D
Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020
[TBL] [Abstract][Full Text] [Related]
8. Role of Adenosine Receptors in Rare Neurodegenerative Diseases with Motor Symptoms.
Beltran-Beltran V; Benetó N; Lapeña-Luzón T; Rodríguez LR; Pallardó FV; Gonzalez-Cabo P
Curr Protein Pept Sci; 2021 Dec; 22(9):675-694. PubMed ID: 34514988
[TBL] [Abstract][Full Text] [Related]
9. Purinergic contribution to amyotrophic lateral sclerosis.
Volonté C; Apolloni S; Parisi C; Amadio S
Neuropharmacology; 2016 May; 104():180-93. PubMed ID: 26514402
[TBL] [Abstract][Full Text] [Related]
10. Role of adenosine A
Pinna A; Serra M; Morelli M; Simola N
J Neural Transm (Vienna); 2018 Aug; 125(8):1273-1286. PubMed ID: 29396609
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic or protective? Neuropeptide Y in amyotrophic lateral sclerosis.
Clark CM; Clark RM; Hoyle JA; Dickson TC
J Neurochem; 2021 Feb; 156(3):273-289. PubMed ID: 32654149
[TBL] [Abstract][Full Text] [Related]
12. Hippocampal synaptic dysfunction in the SOD1
Rei N; Rombo DM; Ferreira MF; Baqi Y; Müller CE; Ribeiro JA; Sebastião AM; Vaz SH
Neuropharmacology; 2020 Jul; 171():108106. PubMed ID: 32311420
[TBL] [Abstract][Full Text] [Related]
13. The molecular link between inefficient GluA2 Q/R site-RNA editing and TDP-43 pathology in motor neurons of sporadic amyotrophic lateral sclerosis patients.
Yamashita T; Kwak S
Brain Res; 2014 Oct; 1584():28-38. PubMed ID: 24355598
[TBL] [Abstract][Full Text] [Related]
14. Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis.
Rué L; Oeckl P; Timmers M; Lenaerts A; van der Vos J; Smolders S; Poppe L; de Boer A; Van Den Bosch L; Van Damme P; Weishaupt JH; Ludolph AC; Otto M; Robberecht W; Lemmens R
Acta Neuropathol Commun; 2019 Jul; 7(1):114. PubMed ID: 31300041
[TBL] [Abstract][Full Text] [Related]
15. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.
Calon F; Dridi M; Hornykiewicz O; Bédard PJ; Rajput AH; Di Paolo T
Brain; 2004 May; 127(Pt 5):1075-84. PubMed ID: 15033896
[TBL] [Abstract][Full Text] [Related]
16. Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease.
Mori A
Int Rev Neurobiol; 2014; 119():87-116. PubMed ID: 25175962
[TBL] [Abstract][Full Text] [Related]
17. Why do motor neurons degenerate? Actualization in the pathogenesis of amyotrophic lateral sclerosis.
Riancho J; Gonzalo I; Ruiz-Soto M; Berciano J
Neurologia (Engl Ed); 2019; 34(1):27-37. PubMed ID: 26853842
[TBL] [Abstract][Full Text] [Related]
18. Insights into the mechanisms of copper dyshomeostasis in amyotrophic lateral sclerosis.
Gil-Bea FJ; Aldanondo G; Lasa-Fernández H; López de Munain A; Vallejo-Illarramendi A
Expert Rev Mol Med; 2017 Jun; 19():e7. PubMed ID: 28597807
[TBL] [Abstract][Full Text] [Related]
19. Altered Intracellular Milieu of ADAR2-Deficient Motor Neurons in Amyotrophic Lateral Sclerosis.
Yamashita T; Akamatsu M; Kwak S
Genes (Basel); 2017 Feb; 8(2):. PubMed ID: 28208729
[TBL] [Abstract][Full Text] [Related]
20. Targeting adenosine A2A receptors in Parkinson's disease.
Schwarzschild MA; Agnati L; Fuxe K; Chen JF; Morelli M
Trends Neurosci; 2006 Nov; 29(11):647-54. PubMed ID: 17030429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
